Skip to main navigation

Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb^®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
- News
- Publications
Careers
Corporate
Investors
Main navigation
Events
Presentations

Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

Science in the service of medicine

About
Pipeline
Clinical Trials
- Patients
- Physicians & Researchers

News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

News Releases

News Releases

Investors

Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter

News Releases

Keyword Search

Year

11/28/22

Vaccinex Announces $3.8 Million Private Placement

11/14/22

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

11/10/22

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

08/15/22

Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs

08/08/22

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

07/29/22

Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease

05/25/22

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

05/16/22

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

04/25/22

Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery

03/31/22

Vaccinex Reports 2021 Financial Results and Provides Corporate Update

03/09/22

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta

02/24/22

Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting

01/27/22

Vaccinex Announces $6.6 Million Private Placement

01/26/22

Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

01/04/22

Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

About
Pipeline
Clinical Trials

News
Careers
Contact

Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com

© 2022 Vaccinex. All rights reserved
Privacy Policy
Site by Minerva